RESUMO
Intestinal fungal dysbiosis is closely associated with the development and progression of many diseases including tumors. The disruption of fungal communities is involved in tumorigenesis and progression through inducing aberrant host immune responses and the production of certain metabolites as well as promoting the establishment of interactions with bacteria. Fungal dysbiosis is a potential marker for early detection of digestive tumors and a factor influencing the efficacy of tumor therapy. Studying the association between gut fungi and digestive tumors may facilitate the prevention, diagnosis and treatment of digestive tumors.
RESUMO
DLC2( Deleted in liver cancer 2), a newly discovered tumor suppressor, was deleted or under-expressed in many tumors, such as in liver cancer, breast cancer and glioma. DLC2 could enhance the activity of GTPase of RhoA and Cdc42, negatively regulate the activity of Rho protein and the downstream signal molecules, and target focal adhesion; DLC2 could react with other proteins via its SAM domain, inducing the protein ubiquitination and degradation; recendy, studies have re-ported that DLC2 and other transcription could regulate each oth-er's level via ceRNA mechanism. Based on the above mechanisms , DLC2 suppresses tumor proliferation, promotes tumor ap-optosis, blocks tumor metastasis, invasion and adhesion, decreases the sternness of tumor cells and enhances drug sensitivity of tumor cells. Therefore, over-expression of DLC2 could be a potential antitumor strategy.